Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00518583
Status:
UNKNOWN
Last Update Posted:
2010-01-15
First Post:
2007-08-16
Brief Title:
Phase II Study in Patients With Operable Breast Cancer
Sponsor:
Aptium Oncology Research Network
Organization:
Aptium Oncology Research Network
Study Overview
Official Title:
A Phase II Study of Pre-Operative Pegylated Liposomal Doxorubicin PLD Paclitaxel and Trastuzumab in Patients With Operable Breast Cancer Over-expressing Her2-neu
Status:
UNKNOWN
Status Verified Date:
2010-01
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will evaluate the safety and efficacy of the combination PLD paclitaxel and trastuzumab in patients with operable breast cancer Patients will be treated with the combination for 18 weeks followed by surgery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None